Kreshnik Zejnullahu, MD
Associate Professor
Medicine
School of Medicine
Education & Training
Show all (3) Hide
- Internal Medicine Residency University of California San Francisco 07/2017
- M.D. Doctor of Medicine University of Massachusetts Medical School 05/2014
- B.A. Biology Bowdoin College 06/2005
Publications (25)
Top publication keywords:
OrchiectomyDrug Resistance, NeoplasmQuinazolinesSpinal Cord DiseasesReceptors, Growth FactorSarcoidosisErbB ReceptorsLung DiseasesPhysical ExaminationAndrogen AntagonistsSpinal CordHemorrhageLung NeoplasmsGene AmplificationQuinazolinones
-
Mycoplasma pneumoniae-Induced Rash and Mucositis in a Previously Healthy Man: A Case Report and Brief Review of the Literature.
Open forum infectious diseases 2020 Gandelman JS, Kim EY, Grzegorczyk AM, Zejnullahu K, Edson RS -
Off Trail, On Track: an Exercise in Clinical Reasoning.
Journal of general internal medicine 2019 Zejnullahu K, Santhosh L, Mourad M, Connor DM -
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
Clinical genitourinary cancer 2017 Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R… -
Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy.
Journal of Clinical Oncology 2017 Archana Anantharaman, Terence W. Friedlander, Christopher J. Welty, Kreshnik Zejnullahu, Jeffrey Hough, Matthew Edwards, Adam Jendrisak, Jerry Lee, Stephanie Greene, Priscilla Ontiveros, Ryon Graf, … -
Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy.
Journal of Clinical Oncology 2017 Terence W. Friedlander, Archana Anantharaman, Christopher Welty, Kreshnik Zejnullahu, Jeffrey Hough, Matthew Edwards, Adam Jendrisak, Jerry Lee, Stephanie Greene, Priscilla Ontiveros, Ryon Graf, Angel…
Show all (20 more) Hide
-
Approaches to minimize castration in the treatment of advanced prostate cancer.
Urologic oncology 2016 Zejnullahu K, Arevalo MG, Ryan CJ, Aggarwal R -
Diffuse Alveolar Hemorrhage: Blood, Sweat and Tears.
Journal of general internal medicine 2016 Zejnullahu K, Khatami S, Manesh RS -
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.
eLife 2015 Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ, Varmus H -
Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.
Cancer research 2012 Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, Ercan D, Christensen JG, Wong KK, Gray NS, Jänne PA -
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
Proceedings of the National Academy of Sciences of the United States of America 2012 Lockwood WW, Zejnullahu K, Bradner JE, Varmus H -
Abstract 4833: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab.
Experimental and Molecular Therapeutics 2012 Kimio Yonesaka, Isamu Okamoto, Satoh Taroh, Kreshnik Zejnullahu, Kazuto Nishio, Masahiro Fukuoka, Pasi A. Janne, Kazuhiko Nakagawa -
OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.
European Journal of Cancer 2011 K. Yonesaka, K. Zejnullahu, I. Okamoto, T. Satoh, F. Cappuzzo, J. Souglakos, J. Engelman, M. Varella-Garcia, K. Nakagawa, P. Jänne -
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.
Science translational medicine 2011 Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K,… -
Abstract 251: Kinome-wide RNAi screen identification of synthetic lethal interactions in BRAF-mutant melanoma.
Cellular and Molecular Biology 2011 Kreshnik Zejnullahu, Tim Wagenaar, Michael R. Green -
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
Oncogene 2010 Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA -
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
Cancer cell 2010 Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, … -
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA -
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee … -
Abstract 4958: Presence of amphiregulin autocrine-loop predicts sensitivity of EGFR wild type cancers to gefitinib and cetuximab.
Clinical Research 2008 Kimio Yonesaka, Kreshnik Zejnullahu, Alison J Homes, Bruce E Johnson, Pasi A Janne -
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
Cancer research 2007 Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne… -
C1-07: IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines.
Journal of Thoracic Oncology 2007 Joon Oh Park, Feng Zhao, Kreshnik Zejnullahu, Emmanuel Normant, Jeffrey A. Engelman, Bruce E. Johnson, Pasi A. Jänne -
C7-07: Presence of amphiregulin autocrine-loop predicts in vitro sensitivity of EGFR wild type NSCLC and HNSCC cell lines to gefitinib and cetuximab.
Journal of Thoracic Oncology 2007 Kimio Yonesaka, Kreshnik Zejnullahu, Alison J. Homes, Bruce E. Johnson, Pasi A. Janne -
D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors.
Journal of Thoracic Oncology 2007 Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen, Rogers M. Rogers, Federico … -
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Science (New York, N.Y.) 2007 Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne … -
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
The Journal of clinical investigation 2006 Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA